Ravi Anand

Summary

Publications

  1. ncbi request reprint Impact of study design and patient population on outcomes from cholinesterase inhibitor trials
    Ravi Anand
    Am J Geriatr Psychiatry 11:160-8. 2003
  2. ncbi request reprint Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine
    Stanford S Jhee
    Clin Neuropharmacol 25:122-3. 2002
  3. ncbi request reprint The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients
    Larry Alphs
    Schizophr Bull 30:577-86. 2004
  4. ncbi request reprint Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial
    Steven G Potkin
    Brain Imaging Center, University of California, Irvine, California 92697 3960, USA
    Biol Psychiatry 54:444-52. 2003
  5. ncbi request reprint The InterSePT scale for suicidal thinking reliability and validity
    J P Lindenmayer
    New York University School of Medicine, New York, NY, USA
    Schizophr Res 63:161-70. 2003
  6. ncbi request reprint Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)
    Herbert Y Meltzer
    Psychiatric Hospital at Vanderbilt, 1601 23rd Ave S, Suite 306, Nashville, TN 37212, USA
    Arch Gen Psychiatry 60:82-91. 2003
  7. ncbi request reprint Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide
    Steven G Potkin
    Department of Psychiatry and Human Behavior, University of California, Room 166, Irvine Hall, Irvine, CA 92697 3960, USA
    Schizophr Res 59:59-66. 2003
  8. ncbi request reprint Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease
    Steven G Potki
    Brain Imaging Center, Department of Psychiatry and Human Behavior, University of California, Irvine 92697, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:713-20. 2002
  9. ncbi request reprint Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?
    P Murali Doraiswamy
    Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:705-12. 2002
  10. ncbi request reprint Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry
    Ravi Anand
    Organon, Oss, The Netherlands
    Alzheimer Dis Assoc Disord 16:S33-9. 2002

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Impact of study design and patient population on outcomes from cholinesterase inhibitor trials
    Ravi Anand
    Am J Geriatr Psychiatry 11:160-8. 2003
    ..Therefore, caution should be taken before making decisions on relative efficacy, safety, and tolerability, because clinical studies are not always directly comparable...
  2. ncbi request reprint Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine
    Stanford S Jhee
    Clin Neuropharmacol 25:122-3. 2002
  3. ncbi request reprint The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients
    Larry Alphs
    Schizophr Bull 30:577-86. 2004
    ..Because of the complexity of the design issues, a steering committee, suicide monitoring board, and publication committee were established to assist with their management...
  4. ncbi request reprint Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial
    Steven G Potkin
    Brain Imaging Center, University of California, Irvine, California 92697 3960, USA
    Biol Psychiatry 54:444-52. 2003
    ..Enhanced ability to reliably identify risk factors for suicidal behavior permits more focused decisions concerning treatment interventions and support services, with potential reduction in lives lost to suicide...
  5. ncbi request reprint The InterSePT scale for suicidal thinking reliability and validity
    J P Lindenmayer
    New York University School of Medicine, New York, NY, USA
    Schizophr Res 63:161-70. 2003
    ..We report the psychometric characteristics of this new scale based on two studies...
  6. ncbi request reprint Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)
    Herbert Y Meltzer
    Psychiatric Hospital at Vanderbilt, 1601 23rd Ave S, Suite 306, Nashville, TN 37212, USA
    Arch Gen Psychiatry 60:82-91. 2003
    ..Approximately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximately 10% die of suicide. Study results suggest that clozapine therapy significantly reduces suicidal behavior in these patients...
  7. ncbi request reprint Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide
    Steven G Potkin
    Department of Psychiatry and Human Behavior, University of California, Room 166, Irvine Hall, Irvine, CA 92697 3960, USA
    Schizophr Res 59:59-66. 2003
    ....
  8. ncbi request reprint Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease
    Steven G Potki
    Brain Imaging Center, Department of Psychiatry and Human Behavior, University of California, Irvine 92697, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:713-20. 2002
    ..To investigate the relationship between activities of daily living (ADL) impairment and Alzheimer's disease (AD) severity in mild to moderately severe AD patients receiving the cholinesterase (ChE) inhibitor rivastigmine...
  9. ncbi request reprint Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?
    P Murali Doraiswamy
    Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:705-12. 2002
    ..The results support the value of early treatment of AD patients, particularly those with moderately severe AD...
  10. ncbi request reprint Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry
    Ravi Anand
    Organon, Oss, The Netherlands
    Alzheimer Dis Assoc Disord 16:S33-9. 2002
    ....
  11. ncbi request reprint Barriers to drug discovery and development for Alzheimer disease
    Howard M Fillit
    The Institute for the Study of Aging, Inc, New York, New York, USA
    Alzheimer Dis Assoc Disord 16:S1-8. 2002
    ..The identified barriers and potential solutions will be discussed here and in the accompanying articles in more detail...
  12. ncbi request reprint Electrocardiographic effects of rivastigmine
    Joel Morganroth
    eResearch Technology, Philadelphia, PA 19103, USA
    J Clin Pharmacol 42:558-68. 2002
    ..Percentage change from baseline for PR, QRS, and QTc intervals was also no different. In conclusion, rivastigmine appears not to produce adverse effects on cardiac function assessed by ECG...
  13. ncbi request reprint A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances
    Mark Weiser
    Sheba Medical Center, Tel Hashomer, Israel
    Int J Geriatr Psychiatry 17:343-6. 2002
    ..This pilot study examined the effects of addition of risperidone 0.5-2 mg/day to patients on rivastigmine 3-12 mg/day, and vice versa...
  14. ncbi request reprint Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future
    Warachal E Faison
    Alzheimer s Research and Clinical Programs, Neurosciences Department, Medical University of South Carolina, Charleston, South Carolina 29406, USA
    Int Psychogeriatr 19:539-58. 2007
    ..for AD to answer two questions: (1) what are the challenges to diagnose and treat AD across different ethnic groups, and (2) are there differences in response to pharmacologic interventions for AD across these different ethnic groups?..